200 related articles for article (PubMed ID: 29174555)
1. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
Horowitz NS; Larry Maxwell G; Miller A; Hamilton CA; Rungruang B; Rodriguez N; Richard SD; Krivak TC; Fowler JM; Mutch DG; Van Le L; Lee RB; Argenta P; Bender D; Tewari KS; Gershenson D; Java JJ; Bookman MA
Gynecol Oncol; 2018 Jan; 148(1):49-55. PubMed ID: 29174555
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
Hamilton CA; Miller A; Casablanca Y; Horowitz NS; Rungruang B; Krivak TC; Richard SD; Rodriguez N; Birrer MJ; Backes FJ; Geller MA; Quinn M; Goodheart MJ; Mutch DG; Kavanagh JJ; Maxwell GL; Bookman MA
Gynecol Oncol; 2018 Feb; 148(2):275-280. PubMed ID: 29195926
[TBL] [Abstract][Full Text] [Related]
3. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
4. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
6. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
7. Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).
Jung DC; Kang S; Kim SC; Kim JW; Nam JH; Ryu SY; Seong SJ; Kim BG
Gynecol Oncol; 2013 Nov; 131(2):336-40. PubMed ID: 23954903
[TBL] [Abstract][Full Text] [Related]
8. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
10. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
11. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
13. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
[TBL] [Abstract][Full Text] [Related]
14. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
[TBL] [Abstract][Full Text] [Related]
16. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.
AlHilli M; Langstraat C; Tran C; Martin J; Weaver A; McGree M; Mariani A; Cliby W; Bakkum-Gamez J
Int J Gynecol Cancer; 2015 Feb; 25(2):193-202. PubMed ID: 25611896
[TBL] [Abstract][Full Text] [Related]
18. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
20. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
